Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of immunogenicity of the 2008-2009 seasonal influenza vaccines by microneutralization test

  • Kim, Seung Youn (Department of Pediatrics, Korean Cancer Center Hospital) ;
  • Kim, Yun Kyung (Department of Pediatrics, Korea University College of Medicine) ;
  • Eun, Byung Wook (Department of Pediatrics, Graduate School of Medicine, Gachon University of Medicine and Science) ;
  • Kim, Nam Hee (Department of Pediatrics, Inje University Ilsan Paik Hospital, Inje University College of Medicine) ;
  • Kang, Eun Kyeong (Department of Pediatrics, Dongguk University Ilsan Hospital) ;
  • Lee, Byong Sop (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lim, Jung Sub (Department of Pediatrics, Korean Cancer Center Hospital) ;
  • Lee, Jun Ah (Department of Pediatrics, Korean Cancer Center Hospital) ;
  • Kim, Dong Ho (Department of Pediatrics, Korean Cancer Center Hospital)
  • Received : 2012.08.16
  • Accepted : 2012.10.18
  • Published : 2012.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: For evaluating the immunogenicity of an influenza vaccine, the microneutralization (MN) test has a higher sensitivity and specificity as compared to the hemagglutination inhibition (HI) test. However, the MN test is more time consuming and is difficult to standardize. We performed the MN test to determine its usefulness as an alternative or complementary test to the HI test for evaluating the immunogenicity of influenza vaccines. Methods: We compared the MN test with the HI test using 50 paired samples taken from a previous clinical study (2008-2009) in Korean children under 18 years of age. Results: The linear correlation coefficients of the 2 tests for H3N2, H1N1, and influenza B were 0.69, 0.70, and 0.66, respectively. We identified a high index of coincidence between the 2 tests. For an influenza vaccine, the postvaccination seroprotection rates and seroconversion rates determined by the MN test were 78.0% and 96.0%, 90% and 42.0%, and 42.0% and 48.0% for H3N2, H1N1, and influenza B, respectively. Geometric mean titer fold increases of H3N2, H1N1, and influenza B were 2.89, 5.04, and 4.29, respectively, and were 2.5-fold higher. We obtained good results in the evaluation of the immunogenicity of the 2008-2009 seasonal influenza vaccines. Conclusion: We found that the MN test was as effective as the HI test. Therefore, we suggest that the MN test can be used as an alternative or complementary test to the HI test for evaluating the immunogenicity of influenza vaccines.

Keywords

References

  1. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31. https://doi.org/10.1056/NEJM200001273420401
  2. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9. https://doi.org/10.1056/NEJM200001273420402
  3. Neuzil KM, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-52. https://doi.org/10.1086/338363
  4. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis 2004;190:1369-73. https://doi.org/10.1086/424527
  5. European Medicines Agency. Committee for proprietary medicinal products (CPMP). CPMP/BWP/214/96. Note for guidance on harmonization of requirements for influenza vaccines. London: European Medicines Agency; c1995-2012 [cited 2004 Dec 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003945.pdf.
  6. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75. https://doi.org/10.1093/oxfordjournals.bmb.a071545
  7. Kayhty H. Immunogenicity assays and surrogate markers to predict vaccine efficacy. Dev Biol Stand 1998;95:175-80.
  8. Arizona Department of Health Services, Division of Public Health Services, Bureau of State Laboratory Services. Modern methods for influenza detection and subtyping [Internet]. Phoenix: Arizona Department of Health Services; c2009-2012 [cited 2012 Nov 22]. Available from: http://www.azdhs.gov/lab.
  9. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990;28:1308-13.
  10. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006;12:55-60. https://doi.org/10.3201/eid1201.051068
  11. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953;98:641-56. https://doi.org/10.1084/jem.98.6.641
  12. World Health Organization, Department of Communicable Disease Surveillance and Response. WHO manual on animal influenza diagnosis and surveillance. 2002.5. Rev. 1 [Internet]. Geneva: World Health Organization; c2012 [cited 2012 Apr 12]. Available from: http://http://www.who.int/csr/resources/publications/influenza/en/ whocdscsrncs20025rev.pdf.
  13. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767-77. https://doi.org/10.1017/S0022172400022610
  14. Benne CA, Harmsen M, De Jong JC, Kraaijeveld CA. Neutralization enzyme immunoassay for influenza virus. J Clin Microbiol 1994;32:987-90.
  15. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
  16. Tobita K, Sugiura A, Enomote C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 1975;162:9-14. https://doi.org/10.1007/BF02123572
  17. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009;58:521-4.
  18. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990;144:595-600.
  19. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 1998;15:1-12.
  20. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 1982;36:1102-8.
  21. Murphy BR, Kasel JA, Chanock RM. Association of serum antineuraminidase antibody with resistance to influenza in man. N Engl J Med 1972;286:1329-32. https://doi.org/10.1056/NEJM197206222862502
  22. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37:529-49. https://doi.org/10.1146/annurev.mi.37.100183.002525

Cited by

  1. A comparison of hemagglutination inhibition and neutralization assays for characterizing immunity to seasonal influenza A vol.10, pp.6, 2012, https://doi.org/10.1111/irv.12408